← Back

TMOThermo Fisher

$662.06+0.83%Delayed market dataLife science toolsMedtech & life sciences · 10 peers →

What's moving this stock lately

0 direct · 1 2nd-order · 0 thematic

Ranked by relevance and recency.

#1Impact0.26%bullish2nd-orderThe Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.34d ago
As a life-science tools and reagents supplier, it indirectly benefits from rising consumables demand in vaccine R&D and manufacturing, though this is a tiny share of total revenue
Impact chain →
Also named: MRNA · BNTX · MRK · PSNL · ADPT · ILMN

🎯 Market expectations

Estimate coverage High · 80/100

Nasdaq analyst consensus · the pre-news baseline

Next quarter (Sep 2026) consensus$6.40Estimate range $6.37 ~ $6.47 · 8 analysts

History: actual vs consensusavg +4.4%

Jun 2026$6.03 vs $5.71+5.6%
Mar 2026$5.44 vs $5.20+4.62%
Dec 2025$6.57 vs $6.43+2.18%
Sep 2025$5.79 vs $5.50+5.27%

The takeaway

Recent results have exceeded consensus by an average of +4.4%, which may have raised expectations for the next report.

Analyst estimates, not our forecast · not investment advice

🏛️ Company factsSEC filings + FINRA official data

Annual revenue $44.6B · latest quarter up 10.5% YoY · profitable (FY net income $6.7B) · short activity below its recent average — bears covering.

FY revenue

$44.6B

2025-12

Latest Q YoY

+10.5%

Gross margin

11.9%

FY net income

$6.7B

Diluted EPS

$17.77

Short volume

39.4%

20d avg 51.6% · shorts covering

🐋 5%+ ownership filings (last 180d)

The following investors reported beneficial ownership of more than 5% in recent SEC filings. "Activist" filers stated an intent to influence control of the company; "Passive" indicates the filer did not report such an intent.

2026-04-30passive (13G)VANGUARD CAPITAL MANAGEMENT LLC

🕰️ Price × news · analysis history

Drag to pan, scroll to zoom · real daily bars and volume

The 4 past analyses on this chart are Pro — price and volume only for now▂ volume

📜 Call history (newest first

Pro only

4 past analyses of this stock, each checked against what the price did afterwards · sign up to view

Start my free trial

Unlock the full analysisStart my free trial

Current conviction

Crowding

Risk temperature

Tail risk

Triggers

Money flow

Insider signals

Unlock the full analysis

See every affected stock, second-order impact and risk factor. Try Pro free for 7 days — no credit card required.

Start my free trial